|
shaanxi weishinuo new material co,.ltd
|
Founded in 2072, Shaanxi Visino New Materials Co., Ltd. is headquartered in the National Science and Technology Enterprise Accelerator Park of Xi 'an High-tech Zone. With R & D centers and production bases in Xi 'an, Shaanxi Province and Lanzhou New District, Gansu Province, it is a state-level high-tech enterprise integrating production, learning and research.
The company is mainly engaged in the research and development, large-scale production and sales of OLED organic light-emitting material intermediates and pharmaceutical intermediates, mainly serving the intermediates supply of OLED industry colleagues and the development and production of innovative drug intermediates. It has the comprehensive ability of route development, pilot and pilot tests to commercialize and expand production services. The company relies on excellent R & D technical strength, excellent product performance, perfect service system, has obtained a good industry recognition, accumulated a wide range of customer resources.
Over the past few years, Visino has always adhered to the "truth-seeking, pragmatic, scientific and rigorous" business philosophy and the "quality is the basis of safety, safety is the premise of quality" production policy, adhere to creating value for customers as the guidance, actively explore new products, new fields, committed to driving the development of the industrial chain, become a leading comprehensive, multi-level platform enterprise.
In the future, Viceno new Materials will continue to climb the scientific and technological peak in related fields, strive to make their own outstanding contributions to product upgrading, energy conservation and environmental protection, win the future with innovation, and change lives with products. |
Send Inquiry
|
|
Zhejiang Brilliant Optoelectronic Technology
|
5,7-Dihydro-indolo[2,3-b]carbazole
OLED intermediate, intermediates, carbazole, 111296-90-3
We specialize in the production of this type of intermediates and can customize them according to customers' specified specifications. |
Send Inquiry
|
Pharma Sources Insight January 2025
